IMPACT OF THE TRIPLED FIXED-DOSE COMBINATION OF ANTIHYPERTENSIVE DRUGS ON CARDIAC ORGAN DAMAGE REGRESSION

2018 ◽  
Vol 36 (Supplement 1) ◽  
pp. e45-e46
Author(s):  
A. Mazza ◽  
L. Schiavon ◽  
C. Rossetti ◽  
S. Lenti ◽  
A.P. Sacco ◽  
...  
Keyword(s):  
Antihypertensive Drugs ◽  
Organ Damage ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Dose Combination

scholarly journals The choice of antihypertensive therapy in correction of cognitive impairments and prevention of dementia: possibilities of valsartan and fixed-dose combination of valsartan and hydrochlorothiazide

2016 ◽  
Vol 13 (4) ◽  
pp. 47-55
Author(s):  
O D Ostroumova ◽  
I A Garelik ◽  
E A Karavashkina
Keyword(s):  
Cognitive Function ◽  
Arterial Hypertension ◽  
Antihypertensive Drugs ◽  
Cognitive Impairments ◽  
Cerebral Protection ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Angiotensin Ii Receptor ◽  
Receptor Blockers ◽  
Dose Combination

This article discusses the definition, classification and pathogenetic mechanisms of cognitive functions in arterial hypertension. The authors discuss the capabilities of the different classes of antihypertensive drugs in correction of cognitive impairments and prevention of dementia. The authors also discuss the advantages of the angiotensin II receptor blockers in prevention of dementia and in their potential mechanisms of cerebral protection. The article describes in detail the possibilities of valsartan in correction of cognitive impairments associated with arterial hypertension, the advantages of valsartan in comparison with calcium antagonists and its unique neuroprotective mechanisms. We show our own results of the study concerning fixed-dose combination of valsartan and hydrochlorothiazide, and find out that this combination has high antihypertensive and cerebral protection (capacity to improve cognitive function) and effectiveness.

scholarly journals Efficacy of a fixed-dose combination (amlodipine/losartan) in the treatment of a patient with arterial hypertension, dyslipidemia and obesity

2020 ◽  
pp. 74-78
Author(s):  
V. P. Mikhin
Keyword(s):  
Arterial Hypertension ◽  
Clinical Case ◽  
Target Organ Damage ◽  
Organ Damage ◽  
Target Organ ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
High Cardiovascular Risk ◽  
Steady Level ◽  
Dose Combination

The article substantiates the feasibility of combination antihypertensive therapy in patients with arterial hypertension without target organ damage and high cardiovascular risk. The authors consider a clinical case of the use of amlodipine and losartan in a fixed-dose combination (Lozap AM) as part of complex therapy in a patient with arterial hypertension, dyslipidemia and obesity. The clinical case showed the ability of the drug to both achieve a steady level of target blood pressure and improve its daily profile by transferring the Night-peaker type to the Non-dipper type.

DoE-Based Analytical Quality Risk Management for Enhanced AQbD Approach to Economical and Eco-Friendly RP-HPLC Method for Synchronous Estimation of Multiple FDC Products of Antihypertensive Drugs

2021 ◽  
Author(s):  
Pintu Prajapati ◽  
Ankita Patel ◽  
Shailesh Shah
Keyword(s):  
Risk Management ◽  
Antihypertensive Drugs ◽  
Hplc Method ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Analytical Quality ◽  
Quality Risk Management ◽  
Rp Hplc ◽  
Dose Combination ◽  
Quality Risk

Abstract According to the literature review, numerous chromatographic methods have been published for estimation of fixed-dose combination products of telmisartan but no reverse-phase high-pressure liquid chromatographic (RP-HPLC) method has been published yet for synchronous estimation of fixed-dose combination (FDC) products of telmisartan to save time, cost and solvent for analysis. Hence, an economical and eco-friendly RP-HPLC method has been developed for synchronous estimation of multiple FDC products of antihypertensive drugs using the quality risk management (QRM) and DoE-based enhanced analytical quality by design approach. The analytical-QRM was started with the identification of potential method risk parameters followed by their risk assessment by risk priority number ranking and filtering. The identified critical method parameters were optimized using the DoE-based central composite design. The method operable design range was navigated and the control strategy was framed for control and mitigation of risk throughout the life-cycle of the developed method. The method was developed using Shimpack Octadecyl silane (ODS) C18 column and acetonitrile-1.0%v/v triethylamine in water (pH 6.0; 45 + 55, %v/v). The developed method was validated as per the International Council for Harmonization Q2 (R1) guideline. The developed method was applied for the analysis of seven different antihypertensive dosage forms. The developed RP-HPLC method can be used as an eco-friendly, robust and economical alternative analytical tool to several published methods for estimation of FDC products of antihypertensive drugs in the pharmaceutical industry.

scholarly journals Organ-protective effect of fixed-dose combination antihypertensive therapy with eprosartan and hydrochlorothiazide for subclinical and clinical target organ damage in hypertensive patients

2012 ◽  
Vol 9 (4) ◽  
pp. 28-34
Author(s):  
N A Koziolova ◽  
A V Bushmakina ◽  
N A Kovalevskaya ◽  
I M Shatunova
Keyword(s):  
Cardiovascular Risk ◽  
Target Organ Damage ◽  
Organ Damage ◽  
Left Ventricular ◽  
Target Organ ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Once Daily ◽  
Dose Combination ◽  
Organ Changes

Aim: to evaluate the efficiency of starting fixed-dose combination therapy with eprosartan and hydrochlorothiazide on the clinical and subclinical parameters of target organ damage in patients with hypertensive disease (HD) irrespective of baseline blood pressure (BP) and cardiovascular risk. Subjects and methods. The study consisted of two parallel substudies. Substudy 1 that screened 3536 workers from industrial enterprises identified 395 (13%) hypertensive patients. Among them, there were 50 (12,7%) untreated patients with HD who had three-component target organ damages: left ventricular hypertrophy, hypertensive nephropathy, peripheral artery lesion. Sixty (15,2%) untreated patients with Stage 1 HD without clinical signs of organ changes were recorded among the same cohort in Substudy 2. In both substudies, Group 1 received a fixed-dose combination of eprosartan mesylate 600 mg once daily and hydrochlorothiazide 12,5 once daily regardless of baseline BP at the onset of the study. Group 2 had monotherapy with enalapril and/or its combination with hydrochlorothiazide depending on the degree of BP elevation and the group of a cardiovascular risk. Results. Starting fixed-dose combination antihypertensive therapy (eprosartan + hydrochlorothiazide) irrespective of baseline BP and cardiovascular risk versus monotherapy with enalapril and/or its free combination with hydrochlorothiazide, which was used in terms of BP level and cardiovascular risk ensured a more significant regression of both clinical and subclinical target organ damages during 6-month therapy according to the changes in left ventricular mass (LVM), LVM index, and tissue inhibitor of type 1 matrix metalloproteinases, microalbuminuria and glomerular filtration rate, intima-media complex thickness during carotid Doppler ultrasound study, and pulse wave velocity in different segments, as evidenced by volumetric sphygmoplethysmography. Conclusions. The use of a fixed-dose combination of eprosartan and hydrochlorothiazide in untreated patients of able-bodied age regardless of baseline BP and cardiovascular risk ensures the regression of target organ damages and the prevention of their development in the absence of organ changes.

Sign in / Sign up

Export Citation Format

Share Document